Article

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

2022-12-13

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Information on the safety and immunogenicity of the omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222 are needed. <h4>Methods</h4> In this ongoing, phase 2/3 trial, 50-μg mRNA-1273.222 (25-μg each ancestral Wuhan-Hu-1 and omicron BA.4/BA.5 spike mRNAs) is compared to 50-μg mRNA-1273, administered as second boosters in adults who previously received a 2-injection (100...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 57490bcc-6bb5-5c39-880e-e5a1372cfa72
DOI: 10.1101/2022.12.11.22283166

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19DOI 10.1101/2022.12.11.22283166Read

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity Read

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read

Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19Semantic proximity Read

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenSemantic proximity Read

Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trialSemantic proximity Read

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron subvariants BA.2, BA.2.12.1 and BA.5Semantic proximity Read

Immunogenicity of the BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity Read

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5Semantic proximity Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read